Table 2

Post-treatment effects of 0.1, 0.9 or 10 mg · ml−1 ofS-(+)-3-IBG or R-(−)-3-IBG on PWL, joint circumference and spontaneous pain rating score

0.1 mg · ml−10.9 mg · ml−110 mg · ml−1
S-(+)-3-IBG
 PWL at 4 h (% baseline), A85  ± 373  ± 277  ± 3
 PWL after drug (% baseline), B86  ± 384*  ± 298*  ± 6
 B − A1  ± 311  ± 321  ± 6
 Score2.1  ± 0.30.6+  ± 0.20.2+  ± 0.2
 Circumference (% baseline)17  ± 118  ± 218  ± 4
R-(−)-3-IBG
 PWL at 4 h (% baseline), A88  ± 472  ± 282  ± 5
 PWL after drug (% of baseline), B82  ± 282*  ± 397*  ± 5
 B − A−6  ± 310  ± 0.515  ± 0.5
 Score2.5  ± 0.40.1+  ± 0.10+  ± 0.3
 Circumference (% baseline)15  ± 314  ± 119  ± 1

Values shown are: PWL after inflammation (4 h), after the drug (5.5 h after inflammation) and the difference between these two values; spontaneous pain rating score and joint circumference after drug treatment. * P < .05 significantly different from 4-h value within the same treatment group (paired t-test).+ P < .05 significantly different from 4-h value within the same treatment group (Wilcoxon test). Values are means (n = 6).